Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours

Project description

Advanced cancer imaging and treatment

Radiotherapy constitutes a significant tool in the fight against cancer. However, conventional radiotherapy often involves high radiation doses, which can lead to significant side effects and harm healthy tissues. To overcome this limitation, the EIC-funded ScanNanoTreat project is developing a transformative theranostic approach that combines advanced photonics, nanotechnology and K-edge imaging. This innovative system enables simultaneous imaging and treatment of solid tumours such as breast and pancreatic cancers. Low-energy X-rays from Spectral Photon Counting CT and optimised nanoprobes can reduce radiation doses by over 30 % compared to traditional methods. By improving precision and minimising radiation exposure time, ScanNanoTreat could significantly enhance treatment outcomes, reduce side effects and lower cancer care costs.

Objective

Cancer treatment is a significant healthcare challenge, costing Europe up to €199 billion annually. The burden will grow substantially, with a projected 60% increase in cancer cases from 2018 to 2040. To address these challenges, the ScanNanoTreat consortium consisting of Claude Bernard Lyon 1 University, Maastricht University, Guerbet, Philips, and Inlecom Commercial Pathways is developing a revolutionary theranostic approach combining advanced photonics and nanotechnology.
The innovative system integrates Spectral Photon Counting Computed Tomography (SPCCT) with X-ray-activated Photodynamic Therapy (X-PDT) using gadolinium-based nanoprobes. This approach enables simultaneous imaging and treatment of solid tumours, with an initial focus on breast and pancreatic cancers.
By leveraging low-energy X-rays and optimized nanoprobes, ScanNanoTreat aims to reduce radiation doses by over 30% compared to conventional radiotherapy. This technology is expected to radically shorten the diagnosis-treatment cycle, leading to improved prognosis and better patient outcomes, and up to 40% reduction in cancer treatment costs. If successfully deployed, ScanNanoTreat could revolutionize the European theranostic market, aiming to capture 10-17% of the projected €493 million market by 2032, suggesting a potential market size of €35-€60 million by 2035. The project will advance the technology from TRL 3 to TRL 5, preparing for clinical trials by 2027 and potential market entry by 2035. Additionally, a business plan and exploitation strategy will be developed, targeting a spinoff creation to commercialize the technology. The support of the EIC Transition grant is crucial to conduct preclinical studies, optimize the SPCCT system, and develop a comprehensive regulatory strategy.
By addressing critical healthcare needs and aligning with EU strategic autonomy in MedTech, ScanNanoTreat will radically improve cancer care and contribute to the sustainability of European healthcare systems.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-TRANSITION-01

See all projects funded under this call

Coordinator

UNIVERSITE LYON 1 CLAUDE BERNARD
Net EU contribution
€ 654 525,00
Address
BOULEVARD DU 11 NOVEMBRE 1918 NUM43
69622 Villeurbanne Cedex
France
Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (5)